Design and Optimization of PLGA Particles to Deliver Immunomodulatory Drugs for the Prevention of Skin Allograft Rejection

Immunol Invest. 2020 Oct;49(7):840-857. doi: 10.1080/08820139.2019.1695134. Epub 2019 Dec 6.

Abstract

Background: Recent advancements in therapeutic strategies have attracted considerable attention to control the acute organs and tissues rejection, which is the main cause of mortality in transplant recipients. The long-term usage of immunosuppressive drugs compromises the body immunity against simple infections and decrease the patients' quality of life. Tolerance of allograft in recipients without harming the rest of host immune system is the basic idea to develop the therapeutic approaches after induction of donor-specific transplant. Methods: Controlled and targeted delivery system by using biomimetic micro and nanoparticles as carriers is an effective strategy to deplete the immune cells in response to allograft in an antigen-specific manner. Polylactic-co-glycolic acid (PLGA) is a biocompatible and biodegradable polymer, which has frequently being used as drug delivery vehicle. Results: This review focuses on the biomedical applications of PLGA based biomimetic micro and nano-sized particles in drug delivery systems to prolong the survival of alloskin graft. Conclusion: We will discuss the mediating factors for rejection of alloskin graft, selective depletion of immune cells, controlled release mechanism, physiochemical properties, size-based body distribution of PLGA particles and their effect on overall host immune system.

Keywords: Acute rejection; PLGA; allograft; biomimetic; targeted delivery.

MeSH terms

  • Allografts
  • Animals
  • Antigens / administration & dosage
  • Antigens / immunology
  • Biomimetics / methods
  • Chemical Phenomena
  • Delayed-Action Preparations
  • Drug Carriers* / chemistry
  • Drug Delivery Systems
  • Drug Design*
  • Drug Development
  • Drug Liberation
  • Graft Rejection / drug therapy
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • Graft Survival / drug effects
  • Graft Survival / immunology
  • Humans
  • Immunologic Factors / administration & dosage*
  • Immunomodulation / drug effects
  • Immunosuppressive Agents / administration & dosage*
  • Nanoparticles / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer* / chemistry
  • Skin Transplantation / adverse effects*
  • Skin Transplantation / methods
  • Transplantation, Homologous

Substances

  • Antigens
  • Delayed-Action Preparations
  • Drug Carriers
  • Immunologic Factors
  • Immunosuppressive Agents
  • Polylactic Acid-Polyglycolic Acid Copolymer